Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Top 3 Stocks on the S&P 500 Last Week


The S 500ʻs winning streak ended at two weeks as the benchmark fell 2.4% last week to 4,224 as of the market close on Friday. Geopolitical strife and a rise in the 10-year Treasury yield to over 5% were the major macro causes of the overall drop.

Last week marked the first time the Treasury yield surpassed 5% since 2007. That has implications for mortgage and loans rates, which, in turn, makes borrowing costs higher and is a drag on many stocks.

This is a big week for earnings as major tech companies like Alphabet (NASDAQ:GOOG), Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN), Visa (NYSE:V), and Meta Platforms (NASDAQ:META) all report. However, last week had some winners too. Here were the top three stocks on the S 500 last week.

1 . VFC Corp.

VFC Corp. (NYSE:VFC) is an apparel company that produces outdoor clothing and gear under brands like North Face, Timberland, Vans and Dickies. The stock jumped 16.6% last week and is now trading at around $18 per share. However, even after that increase, it is still down 35% year to date.

One catalyst for VFC last week was the strong retail sales report, which showed that sales climbed 0.7% in September to $705 billion. It was better than the 0.3% estimate and marked the sixth consecutive month of retail sales growth in the U.S.

However, the larger catalyst was the news that activist investor Engaged Capital acquired a stake in the retailer and began pushing for about $300 million in cost cuts, a pause on acquisitions, and board changes, among other requests. The market saw the activist's involvement as a positive step for the struggling stock, which is down 35% YTD. Stay tuned for VFCʻs third-quarter earnings on Oct. 30.

2. DexCom

DexCom (NASDAQ:DXCM) has been on a rollercoaster the past few weeks, but this past week was an up week as the stock surged 12.8%. The medical device manufacturer makes continuous glucose monitors (CGMs) for people with diabetes, among other products. The stock is now trading at just over $85 per share, down 24% YTD.

DexComʻs stock had fallen in recent weeks on concerns that the success of glucagon-like peptide-1 (GLP-1) drugs like Ozempic and Mounjaro for weight loss among diabetes patients may reduce the need for CGMs. However, DexCom said the opposite -- that they lead to higher usage of CGMs.

DexCom received a boost last week when analysts from Leerink initiated coverage of its stock with an outperform rating, calling the GLP-1 concerns overblown. Leerink set a price target of $110, which is a 29% gain over the current stock price. DexCom is scheduled to report Q3 earnings on Oct. 26.

3. Netflix

The TV-streaming company Netflix (NASDAQ:NFLX) was the third-biggest gainer last week, soaring 12.7%. Netflix is now up 36% YTD and trading at around $401 per share, placing it among the top performers on the S 500 this year.

Netflixʻs jump this past week was due mainly to its excellent third-quarter earnings report. The company posted an 8% year-over-year increase in revenue to $8.5 billion and a 20% rise in net income to $1.7 billion, or $3.73 per share. Both beat the consensus estimates.

Global paid memberships increased 11% year over year, and paid net additions were 8.8 million, up from 5.9 million in Q2 and 2.4 million in the year-ago quarter. It was the biggest quarterly net add since the start of the pandemic and shows that Netflixʻs recent crackdown on password-sharing is working.

For the fourth quarter, revenue is projected at $8.7 billion, an 11% year-over-year gain, while net paid additions are expected to be similar to Q3.


Source valuewalk

Dexcom Inc. Stock

€116.42
0.210%
Dexcom Inc. gained 0.210% compared to yesterday.
Dexcom Inc. is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 136 € there is a slightly positive potential of 16.82% for Dexcom Inc. compared to the current price of 116.42 €.
Like: 0
Share

Comments